By Sheeba M. | Weedstock Market Intelligence | Saturday, October 3, 2026
The DEA’s proposed rescheduling of cannabis from Schedule I to Schedule III under the Controlled Substances Act continues to advance through its administrative process, with October representing a potential inflection point for federal cannabis policy.
Where the DEA Process Stands
The formal rulemaking process has completed its public comment review phase. The remaining procedural steps are:
- DEA Administrator Final Review — In progress. Reviewing ALJ recommendations and public comment summary.
- OMB Regulatory Review — Required for economically significant rules. OMB has up to 90 days but has historically fast-tracked high-priority rules.
- Federal Register Publication — Final rule becomes effective 30 days post-publication.
Industry legal analysts report no Federal Register publication as of Friday’s close, but the October window remains open. Congressional pressure from both sides of the aisle has been directed at DEA to finalize the rule before year-end.
280E Tax Relief: What It Means for Operators
Section 280E of the Internal Revenue Code prohibits cannabis businesses from deducting ordinary business expenses. The effective tax burden for most MSOs runs 60-80% of gross profit, compared to 21% for typical C-corporations.
Industry tax attorneys broadly expect the IRS to issue guidance within 60-90 days of a final DEA rule. For a company like CURLF, 280E relief alone could add $80-120M annually to operating cash flow.
Congressional Response
The bipartisan SAFE Banking Act has seen renewed momentum as rescheduling advances:
- Senate Banking Committee: Majority and minority leadership have co-sponsored the current SAFE Banking iteration
- House Commerce: Cannabis provisions have been attached to broader financial services markup
- White House: Stated position remains supportive of both rescheduling and banking access
Market Impact Analysis
The rescheduling catalyst has been partially priced into cannabis equities. Expected scenarios:
- Full Schedule III final rule (65% probability): 40-70% upside in major MSOs within 30 days. MSOS ETF inflows could exceed $500M in first month.
- Delayed to Q1 2027 (25% probability): Near-term consolidation, but no fundamental thesis change.
- Administrative block (10% probability): Sharp near-term selloff, but precedent strongly favors DEA authority to reschedule.
Cannabis operators including GTBIF, TCNNF, and OGI have each incorporated Schedule III scenarios into their Q4 guidance ranges.
LP and International Operators
Canadian Licensed Producers like CGC (Canopy Growth) and OGI (Organigram) have maintained U.S. option structures specifically staged for a rescheduling trigger. U.S. market access — currently prohibited by Schedule I status for federally regulated entities — would open substantially upon final rule publication.
Sheeba’s Regulatory Take
The DEA process is grinding forward. October remains live. The 280E math alone makes Schedule III one of the most consequential regulatory events in cannabis equity history. Investors who have done their homework are positioned. Make sure you are in that group.
Sheeba M. covers cannabis capital markets and regulatory affairs for Weedstock. This is not legal or investment advice.